The Amyloid Files: Cracking the Case – Evolving Strategies in Cardiac Amyloidosis-Uncovering the Future

Video Transcription

Video Summary

The lecture discusses advancements in diagnosing and treating ATTR amyloidosis. Promising tools include AI algorithms for ECG analysis, novel PET radiotracers, and blood biomarkers like TAD-1, improving early detection. Therapeutically, Aciramidis is being trialed for those at genetic risk, while Eplantracin offers monthly subcutaneous treatment for ATTR polyneuropathy. Cutting-edge CRISPR-Cas9 therapy, NexZ, aims to silence the TTR gene with one infusion. NI006, a monoclonal antibody, shows potential for disease regression by promoting amyloid clearance. These advancements promise to transform the prognosis and management of ATTR amyloidosis.

Keywords

ATTR amyloidosis

AI algorithms

CRISPR-Cas9

Aciramidis

monoclonal antibody